Over the past month, we gained some positive insights into the effectiveness ketamine in the real-world data. The official results of the first trial using LSD to treat generalized anxiety disorder were published and researchers continue to learn more about what psychedelics are doing in the brain.
While many of us had the chance to enjoy a vacation this summer, psychedelic researchers continued their hard work. They continued to unearth more about the therapeutic potential of these compounds. A big real-world study on at-home ketamine therapy finds promising results. At the same time, psilocybin was tested for alcoholism in a double-blind, placebo-controlled study design for the first time.
Summer is officially here and psychedelic researchers are continuing their efforts to turn these medicines into viable therapy options. Despite relatively few clinical trials being published over the month of June, we’re continuing to learn more about the effects of psychedelics through the reanalysis of existing datasets and surveys.
May was another busy month for psychedelic research as we gained further insight into how psychedelics work in the brain and much more.
Over the month of April, we continued to learn more about psychedelic medicine as we added over 80 papers to our database. Here you’ll find a recap of of the most significant publications.
March was another busy month in psychedelic medicine with nearly 100 publications of trials, surveys, reviews and the rest. Notably, psilocybin was compared to LSD while MDMA may have promise for eating disorders.
February was another productive month for psychedelic research. LSD vs psilocybin, and a 12-month follow-up for a depression trial are featured, next to 34 other research papers.
Researchers in the field of psychedelics hit the ground running at the turn of the new year. January brought with it the largest published clinical trial with psilocybin to date. While ketamine was shown to be effective in treating patients with alcohol use disorder, the same can’t be said for PTSD. A host of reviews provide food for thought on a range of psychedelics and their mechanism of action.
December was another busy month in the world of psychedelic research as 2021 came to a close. The benefits of microdosing remain in dispute, the use of virtuality reality in tandem with psychedelics is further discussed, while we simultaneously gained further insight as to how different psychedelics work in the brain for different disorders, through both experiments and reviews.
November proved to be another productive month for psychedelic research. A variety of surveys looked at how psychedelics alter beliefs, reduce opioid use, and the effects of microdosing. A finished Phase I trial clear 5-MeO-DMT for the next step, cannabis intensifies a psychedelic experience, and psychedelics may help with Alzheimer’s.